Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Sophie Dessureault is a Gastroenterologist and a Surgical Oncologist in Tampa, Florida. Dessureault has been practicing medicine for over 33 years and is rated as an Elite expert by MediFind in the treatment of Appendix Cancer. She is also highly rated in 6 other conditions, according to our data. Her top areas of expertise are Appendix Cancer, Anal Cancer, Familial Colorectal Cancer, Colostomy, and Hernia Surgery. Dessureault is currently accepting new patients.
Panayotis Ledakis is an Oncologist and a Hematologist Oncology expert in Baltimore, Maryland. Ledakis has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Appendix Cancer. He is also highly rated in 75 other conditions, according to our data. His top areas of expertise are Appendix Cancer, Pseudomyxoma Peritonei, Desmoplastic Small Round Cell Tumor, and Colorectal Cancer. Ledakis is currently accepting new patients.
Michelle Sittig practices in Ahmedabad, India. Sittig is rated as an Elite expert by MediFind in the treatment of Appendix Cancer. She is also highly rated in 1 other condition, according to our data. Her top areas of expertise are Appendix Cancer, Pseudomyxoma Peritonei, Ovarian Cancer, and Endometrial Stromal Sarcoma.
Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is heated chemotherapy that washes the abdomen. CRS and HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve results of CRS and HIPEC by choosing the chemotherapy drugs used in HIPEC.
Summary: This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.